Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

A Critical Review of CTRI Registered Trials of Shushkakshipaka Ayurvedic Management

View through CrossRef
Acharya Sushruta and Acharya Vagbhata, both of them have classified Shushkakshipaka under Sarvagataroga. Symptoms of Shushkakshipaka described by Sushruta are Sudarun Paribodhanam (dryness of eyelids), Ruksha Vartma (dryness of eyes), and Avil Darshana (blurred vision) and Darun Vartma (stiffness of eyelids). This study scrutinized the trials registered for Shushkakshipaka from the database to detect patterns in methodology (study design, sample size) of trials. Material and Method: This was an observational study that analysed the CTRI registered trials for Shushkakshipaka between March 2012 and July 2024. A trial search was conducted on the CTRI database to include all types of studies registered for Shushkakshipaka with keywords like “Shushkakshipaka” and studies conducted on conditions other than Shushkakshipaka were excluded. Result: There were total 51 studies which were analysed from Ayurveda stream. Most of these studies were registered from Maharashtra state [n-19] i.e., 39.75%, most of the study conducted as randomized trial (n-39), parallel group trials (n-39). Conducted as double arm study 76.47%. Most of the study Shushkakshipaka related studies registered on CTRI is maximum in year 2024 (n-11). There are 22 studies having age group in between 1 year and 1 year 6 months i.e., 43.13%. Maximum studies conducted in age group between 18- 60 years of age (n-39) i.e., 76.47%. There were 34 studies including kriyakalpa as intervention i.e., 66.66%. Conclusion: The present review is an attempt to analyse the CTRI-registered Shushkakshipaka clinical trials, which show the general characteristics of trials along with study design and setups. Although there is a surge of clinical trials on CTRI regarding Ayurveda for Shushkakshipaka, the methodological information is not more elaborative and there is large scope for improvement.
Title: A Critical Review of CTRI Registered Trials of Shushkakshipaka Ayurvedic Management
Description:
Acharya Sushruta and Acharya Vagbhata, both of them have classified Shushkakshipaka under Sarvagataroga.
Symptoms of Shushkakshipaka described by Sushruta are Sudarun Paribodhanam (dryness of eyelids), Ruksha Vartma (dryness of eyes), and Avil Darshana (blurred vision) and Darun Vartma (stiffness of eyelids).
This study scrutinized the trials registered for Shushkakshipaka from the database to detect patterns in methodology (study design, sample size) of trials.
Material and Method: This was an observational study that analysed the CTRI registered trials for Shushkakshipaka between March 2012 and July 2024.
A trial search was conducted on the CTRI database to include all types of studies registered for Shushkakshipaka with keywords like “Shushkakshipaka” and studies conducted on conditions other than Shushkakshipaka were excluded.
Result: There were total 51 studies which were analysed from Ayurveda stream.
Most of these studies were registered from Maharashtra state [n-19] i.
e.
, 39.
75%, most of the study conducted as randomized trial (n-39), parallel group trials (n-39).
Conducted as double arm study 76.
47%.
Most of the study Shushkakshipaka related studies registered on CTRI is maximum in year 2024 (n-11).
There are 22 studies having age group in between 1 year and 1 year 6 months i.
e.
, 43.
13%.
Maximum studies conducted in age group between 18- 60 years of age (n-39) i.
e.
, 76.
47%.
There were 34 studies including kriyakalpa as intervention i.
e.
, 66.
66%.
Conclusion: The present review is an attempt to analyse the CTRI-registered Shushkakshipaka clinical trials, which show the general characteristics of trials along with study design and setups.
Although there is a surge of clinical trials on CTRI regarding Ayurveda for Shushkakshipaka, the methodological information is not more elaborative and there is large scope for improvement.

Related Results

Indian Clinical Trials on COVID-19: A Review of Clinical Trials Registry of India (CTRI) (Preprint)
Indian Clinical Trials on COVID-19: A Review of Clinical Trials Registry of India (CTRI) (Preprint)
BACKGROUND The COVID-19 has impacted the world in an unprecedented way. More than 200 countries have been affected because of this novel coronavirus. Global...
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Abstract The Physical Activity Guidelines for Americans (Guidelines) advises older adults to be as active as possible. Yet, despite the well documented benefits of physical activi...
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Abstract Introduction Although the efficacy of PD-L1 blockade has been evaluated in analyses that combine pharmacologically distinct antibodies, the specific efficacy and safety of...
GENERALIZED ANXIETY DISORDER IN CONTEMPORARY TIMES: A CRITI-CAL REVIEW THROUGH THE LENS OF AYURVEDA
GENERALIZED ANXIETY DISORDER IN CONTEMPORARY TIMES: A CRITI-CAL REVIEW THROUGH THE LENS OF AYURVEDA
Background: Generalised Anxiety Disorder (GAD) is a prevalent mental health condition characterised by ex-cessive, uncontrollable worry about various aspects of life. In contempora...
A Systemic Review on Comparative Study of Traditional And Modern Methods of Preparation of Ayurvedic Medicines
A Systemic Review on Comparative Study of Traditional And Modern Methods of Preparation of Ayurvedic Medicines
Affordable, high-quality Ayurvedic remedies may be the answer to today's healthcare demands of the Indian and worldwide communities. In order to scale up manufacturing of the medic...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract Introduction Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...

Back to Top